Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

AVITHRAPID Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases

Coordinator
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eV, Germany
Runs
1 January 2024 to 30 June 2028
Status
Running
EU funding
€7.5m
Total cost
€7.5m
Partners
21 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101137192

What the project is doing

In the project's own words, from its summary on CORDIS.

The European Consortium ""Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases"" (AVITHRAPID) aims to support the search for novel broad-spectrum antiviral compounds by advancing multiple approaches. Building on a pre-existing set of bioactive small molecules, which are at least at the validated hit level, AVITHRAPID strives for the development of pre-clinical candidates targeting several viruses.

This will be achieved by combining the relevant expertisefor pre-clinical drug discovery, including molecular modeling, biochemical and cell-based assays, X-ray crystallography, medicinal chemistry, biophysical binding studies, ADMETox profiling, in vitro and in vivo PK, as well as animal disease models. In addition, the consortium aims to conduct a Phase 2a clinical trial for a small molecule developed against Zika virus.

Moreover, the consortium aims to identify and validate further viral targets and thereby contribute to the search for novel antiviral targets. As a consequence of the activities in AVITHRAPID, an early-stage drug discovery pipeline will be established that can be used to rapidly identify and develop novel antiviral compounds against emerging diseases.""

Topics

Who is involved

OrganisationCityCountryRole
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eVMunchenGermanyCoordinator
Chelonia SALuganoSwitzerlandAssociatedpartner
Schweizerisches Tropen Und Public Health InstitutAllschwilSwitzerlandAssociatedpartner
Vsb - Technical University of OstravaOstrava PorubaCzechiaParticipant
Helmholtz-Zentrum Fur Infektionsforschung GmbHBraunschweigGermanyParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceThird party
Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnementParisFranceParticipant
Universite De ToursToursFranceParticipant
Dompe Farmaceutici SpAMilanoItalyParticipant
Elettra - Sincrotrone Trieste ScpaBasovizza TriesteItalyParticipant
Euresist Network GeieRoma RmItalyParticipant
Istituto Nazionale per Le Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura a Carattere ScientificoRomaItalyParticipant
Universita Degli Studi Della TusciaViterboItalyParticipant
Universita Degli Studi Di CagliariCagliariItalyParticipant
Universita Degli Studi Di Napoli Federico IiNapoliItalyParticipant
Universita Degli Studi Di PerugiaPerugiaItalyParticipant
Universita Degli Studi Di Roma Tor VergataRomaItalyParticipant
Universita Degli Studi Di SienaSienaItalyParticipant
Valsts zinatniskais instituts ""Nacionalais petniecibas un inovaciju instituts""""RigaLatviaParticipant
First Health Pahrmaceuticals BVAmsterdamNetherlandsParticipant
Fundacao Gimm - Gulbenkian Institute for Molecular MedicineLisboaPortugalParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI